Posters

Starlight Posters

November 24, 2024

A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) alone and in combination with Spironolactone in IDH wild type Glioblastoma at First Progression

STAR-001 (LP-184) is a promising chemotherapeutic with potential clinical translation in GBM patients as monotherapy or combination therapy
Button Text
August 12, 2023

STAR-001 (LP-184), a clinical stage acylfulvene-derived tumor site activated small molecule, inhibits adult and pediatric CNS tumor cell growth

Blood-brain barrier (BBB) permeable agents effective against recurrent, chemotherapy-resistant CNS tumors are urgently needed, particularly in Glioblastoma multiforme (GBM) and atypical teratoid/rhabdoid tumors (ATRT)
Button Text
November 20, 2022

Preclinical efficacy of STAR-001 (LP-184), a tumor site activated synthetically lethal therapeutic, in glioblastoma

Temozolomide, the most effective standard-of-care chemotherapy for newly diagnosed glioblastoma, is ineffective in ~70% of patients due to MGMTdriven resistance and there is no effective chemotherapy for recurrent GBM
Button Text
April 13, 2022

STAR-001 (LP-184), a tumor site activated small molecule synthetic lethal therapeutic, is effective in central nervous system cancers

Glioblastoma multiforme (GBM) and atypical teratoid/rhabdoid tumors (ATRT). These represent 2 extremely aggressive and lethal types of CNS malignancies sharing a median overall survival of 12- 18 months and 5-year survival rate of 5 to 30% in the US
Button Text
November 21, 2021

Utility of STAR-001 (LP-184) as a CNS-bioavailable agent in glioblastoma, having been granted orphan drug designation

Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer with a 5-year survival rate of only 5% [1] with marginal improvements in this statistic over the last two decades.
Button Text
April 29, 2020

Use of expression-based machine learning-derived gene signatures to predict drug sensitivity profile and identify cancer indications for STAR-001 (LP-184)

A novel clinical agent, LP-184, is being developed by Lantern Pharma in conjunction with a dedicated machine learning-guided response signature, to allow optimal benefit and positioning of LP-184 through genomics-guided therapy.
Button Text